CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment

Rhea-AI Summary

CNS Pharmaceuticals (NASDAQ:CNSP) announced its participation in a Virtual Investor KOL Connect segment featuring Professor Michael Weller, Chairman of the Department of Neurology at the University Hospital in Zurich and National Coordinating Investigator for CNS's Berubicin study. The segment focused on glioblastoma multiforme (GBM), discussing unmet medical needs, current treatments, and Berubicin's potential as a solution for this condition.

Segment featuring leading Neuro-Oncologist and Glioblastoma Key Opinion Leader, Professor Michael Weller

Access the segment here

HOUSTON, TX / ACCESSWIRE / November 4, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that it participated in a Virtual Investor KOL Connect segment.

As part of the event, Professor Michael Weller, a leading Neuro-oncologist who currently serves as the Chairman of the Department of Neurology at the University Hospital in Zurich, Switzerland and as the National Coordinating Investigator for CNS Pharmaceuticals' potentially pivotal study of Berubicin, discussed the unmet need in glioblastoma multiforme (GBM), the current treatment landscape and the potential for Berubicin to provide a solution for this devasting disease.

The Virtual Investor KOL Connect segment featuring CNS can be accessed here.

About CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.

For more information, please visit www.CNSPharma.com, and connect with the Company on X, Facebook, and LinkedIn.

CONTACTS:

Investor Relations Contact

JTC Team, LLC
Jenene Thomas
908.824.0775
CNSP@jtcir.com

SOURCE: CNS Pharmaceuticals, Inc.

View the original press release on accesswire.com

FAQ

What did Professor Michael Weller discuss in CNS Pharmaceuticals' (CNSP) Virtual Investor KOL Connect segment?

Professor Weller discussed the unmet need in glioblastoma multiforme (GBM), the current treatment landscape, and Berubicin's potential as a treatment solution.

What is Professor Michael Weller's role in CNS Pharmaceuticals' (CNSP) Berubicin study?

Professor Weller serves as the National Coordinating Investigator for CNS Pharmaceuticals' potentially pivotal study of Berubicin.

What is CNS Pharmaceuticals' (CNSP) focus area in drug development?

CNS Pharmaceuticals specializes in developing novel treatments for primary and metastatic cancers in the brain and central nervous system.